Riding high after laying to rest its patent skirmish, Alnylam Pharmaceuticals Inc. priced its public offering of 8 million shares without a discount, selling them at Tuesday's closing price of $21.32, for net proceeds of about $151.1 million, or about $173.8 million if the underwriters exercise their full overallotment option of 1.2 million shares.